The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.

Inclusion Criteria:

• primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
• single lesion and longest tumor diameter were 5-10cm;
• CP-A or B classification;
• Eastern Cooperative Oncology Group (ECOG) score 0-1;
• distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm
• unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc.
• rejecting other therapies such as resection, liver transplantation, etc.
• platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
• patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.

Exclusion Criteria:

• tumor thrombus;
• lymph node involvement;
• extrahepatic metastasis.

The large HCC patients who receive SBRT with or without TACE.